Pandorum ties up with Bharat Biotech arm Nucelion to scale exosome therapies across APAC
ADVERTISEMENT
Bengaluru-based Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, has joined hands with vaccine maker Bharat Biotech's wholly owned subsidiary Nucelion Therapeutics to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region.
Nucelion is a specialised contract research, development, and manufacturing organisation (CRDMO) based in Hyderabad. By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward.
“Pandorum is building a global regenerative medicine platform designed for scale, consistency, and partnership. As our programmes advance toward clinical and commercial milestones, establishing robust, regionally aligned manufacturing infrastructure is a strategic priority,” Tuhin Bhowmick, Co-Founder and Chief Executive Officer, Pandorum Technologies, said.
Nucelion will provide end-to-end manufacturing support, including process scale-up, GMP-compliant production, and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells.
“We are pleased to partner with Pandorum Technologies on the development of Kuragenx, an innovative exosome-based therapy with the potential to redefine the treatment paradigm for ocular diseases,” said Raghu Malapaka, CBO, Nucelion Therapeutics. “Our advanced manufacturing platforms and quality systems are designed to support complex biologics, and we look forward to enabling the scalable production of Pandorum’s designer exosome-based assets for patients across the APAC region.”
January 2026
Netflix, which has been in India for a decade, has successfully struck a balance between high-class premium content and pricing that attracts a range of customers. Find out how the U.S. streaming giant evolved in India, plus an exclusive interview with CEO Ted Sarandos. Also read about the Best Investments for 2026, and how rising growth and easing inflation will come in handy for finance minister Nirmala Sitharaman as she prepares Budget 2026.
Pandorum’s current programmes span ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome (SJS), Neurotrophic Keratitis. The company plans to expand its disease modifying treatments to reverse degenerative changes of skin, pulmonary, and other organ systems affected by inflammation, vascular pathologies, and fibrosis.
“The strategic collaboration of Pandorum and Nucelion to manufacture advanced therapeutics sends out an important signal towards the readiness of both Innovate and Make in India, for addressing unmet global clinical needs,” Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council, Department of Biotechnology, said.
Pandorum is pioneering a tunable exosome platform designed to reprogram diseased tissues by precisely modulating intercellular communication pathways. The company’s approach is grounded in the principle that tissues are learnable, dynamic biological systems, and that controlled delivery of biologically encoded signals—via designer extracellular vesicles (exosome)can restore tissue structure and function in conditions driven by inflammation, fibrosis, and loss of regenerative capacity.